Novartis' Simbrinza approved for glaucoma treatment in the EU
- Novartis' Simbrinza (brinzolamide/brimonidine) is the only fixed-dose combination therapy for glaucoma that does not involve a beta-blocker.
- The EU Commission approved Simbrinza eye drops for the treatment of elevated intraocular pressure (IOP) in adults with glaucoma or ocular hypertension.
- Beta-blockers are not intended for use in patients with certain respiratory or cardiac conditions, so Simbrinza represents an important treatment option for these individuals.
Simbrinza was approved by the FDA in 2013. There continues to be a need for effective approaches to the management of open-angle glaucoma, which represents 74% of all cases of glaucoma worldwide. Not only does Simbrinza offer the advantage of not having a beta-blocker -- it offers a simplified dosing regimen compared with brinzolamide alone.
This is important given that adhering to a treatment schedule is a challenge for this population. In fact, 80% of patients with glaucoma deviate from their drug regimen. Novartis hopes to improve treatment rates in this population of patients, while helping patients retain their vision.
- Pharma Times EU approves Novartis glaucoma combo